BTMDNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31

biote Corp.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026

$1.08−0.00 (-0.46%)

Close on Oct 19, 2026

Market cap: $30.92M
P/E (TTM): 10.8
Dividend yield: –

biote Corp. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	192	197	185	165	139
Cost of Revenue	55	58	58	55	49
Gross Profit	137	139	127	110	91
Selling, General & Admin	102	107	99	171	49
Advertising Expenses	5.90	5.90	5.10	–	–
Operating Income	36	32	29	-61	35
Other Non-Operating Income	2.03	-31	-29	62	-1.66
Asset Impairment Charges	0	0	0	0	0
Gain (Loss) on Investments	–	–	–	–	0.08
Pretax Income	38	1.02	-0.12	1.71	33
Income Tax Expense	5.99	0.97	2.68	0.39	0.29
Net Income incl. Noncontrolling Interests	32	0.05	-2.81	1.32	33
Minority Interest in Earnings	4.55	-3.11	-6.12	2.29	–
Net Income	27	3.16	3.32	-0.97	11
Net Income to Common	27	3.16	3.32	-0.97	–
EPS (Basic)(per share)	0.86	0.09	0.13	-0.12	–
EPS (Diluted)(per share)	0.74	0.09	0.13	-0.12	–
Shares Outstanding (Basic, Weighted)(shares)	31	34	26	8.06	–
Shares Outstanding (Diluted, Weighted)(shares)	37	34	26	8.06	–
EBITDA	39	35	32	-59	36

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 68.6%
Operating margin: 8.0%
Net margin: 3.2%
Return on equity, FY2025: -32.9%

Financial strength

Current ratio: 1.43
Debt to equity: -1.85
Debt to assets: 119.5%
Cash to current liabilities: 37.1%

Valuation

P/E ratio: 10.8
Price to sales: 0.17
Price to book: –
Dividend yield: –